UKUK

100% premium: Novartis buys antibiotics specialists Neutec Pharma

21.07.2006

London – Another UK biotech company was taken over when Novartis signed a recommended all-cash offer worth Euro435 million for the antibiotics specialists Neutec pharma. The Swiss pharma giant paid more than twice of the Manchester-based company’s market capitalization before the takeover approach. Buying Neutec gives Novartis access to two advanced stage antibody products for serious hospital-acquired infections: Mycograb, for treating systemic fungal infections and Aurograb, for treating methicillin-resistant Staphylococcus aureus. Daniel Vasella, CEO of Novartis, said the products “promise to dramatically improve treatments in the area and will also enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio.” Mycograb has been filed in Europe and has been approved for compassionate use, while Aurograb is in phase III. NeuTec has retained 100% ownership of its products. The buyout is a big payday for the founders Ruth Mathews and James Burnie, who still own a 7% stake. During the takeover negotiations the founders secured NeuTecs operations at the current facility in Manchester for at least two years. The sale of the company came just three weeks after AstraZeneca agreed to buy Cambridge Antibody for Euro1.1 billion. Besides the Neutec deal the antibiotics market has seen amany known players disappear. One of the most prominent was the US-based Vicuron, bought by Pfizer for $1.9 billion. New companies have nevertheless emerged as Roche (Basilea), Sanofi-Aventis (Novexel), Sandoz (Nabriva) and Bayer (Aicuris) span out their infectious disease businesses.

Politics / Law

29.04.2011

A group of 13 internationally renowned stem cell scientists warn in a letter to Nature (2011, Vol. 572, S. 418) that the field is under serious threat from a case which is before the European Court of Justice. The academics said...

Miscellaneous

27.04.2011

Parma - The European Food Safety Authority (EFSA) has set its eyes on saving genes from damage by substances in food and feed. Before 31 May 2011, stakeholders and interested parties can comment on a draft opinion from EFSA's...

Politics / Law

15.04.2011

Five years ago, the European Commission adopted the Health Claims Regulation (EC 1924/2006) to protect consumers from misleading claims about positive health effects of foods. According to the Regulation, health claims must be...

Tech Review

15.04.2011

Personalised medicine – the buzzword that describes selecting and treating defined patient subpopulations that respond to a specific drug treatment, thereby allowing physicians to pursue more stratified medicine. Pharma and...

Politics / Law

14.04.2011

Stem-cell based therapies and drug screening tests are being developed all over the world – but they won’t be in Europe if the 13 Grand Chamber judges of the European Court of Justice (ECJ) in Luxembourg follow a recommendation...

Politics / Law

14.04.2011

On both sides of the Atlantic, the past year has seen a number of developments that stand to make obtaining and enforcing biotechnological patents more difficult. Some of this development is still in flux, or has not been...

Politics / Law

14.04.2011

Brussels – For the greater good of Brussels and the development of agricultural research and innovation, we decided to extend our horizons a little this issue. Let's turn our attention first to a very useful report from the UK:...

Tech Review

14.04.2011

The demand for reliable and fast in vitro diagnostics in human medicine has increased dramatically in the last decade, while over the past few years the development and application of molecular diagnostic techniques has initiated...

Tech Review

14.04.2011

Long before hospitals had laboratories for testing human specimens – before people had even begun to dream of molecular diagnostics – phys­icians diagnosed diabetes by tasting the urine of their patients. Although they wouldn’t...

Displaying results 161 to 170 out of 1983

< Previous 161-170 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/16/article/100-premium-novartis-buys-antibiotics-specialists-neutec-pharma.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%

FLOP

  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 20.04.2015

Current issue

All issues